Skip to content

Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System

A Prospective, Comparative Effectiveness Randomized Controlled Trial of SPR Peripheral Nerve Stimulation (PNS) Therapy for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Utilizing Preoperative Lead Placement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03286543
Enrollment
47
Registered
2017-09-18
Start date
2017-09-05
Completion date
2020-04-15
Last updated
2021-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Disorder, Pain, Postoperative Pain, Total Knee Arthroplasty, Total Knee Replacement

Keywords

electrical stimulation, neurostimulation, TKA pain, pain following total knee replacement, total knee arthroplasty

Brief summary

The purpose of this study is to determine if electrical stimulation (small levels of electricity) in addition to the standard of care can safely and effectively reduce pain following total knee replacement more than the standard of care, alone. This study involves a device called the SPRINT Beta System. The SPRINT Beta System delivers mild electrical stimulation to nerves in the leg that received the knee replacement. The SPRINT Beta System includes a small wire (called a lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator). About half the subjects in this study will receive the SPRINT Beta system (treatment group) and half will not (control group). Both groups will receive the standard of care.

Interventions

DEVICESPRINT Beta System

The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator).

Sponsors

SPR Therapeutics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Half of the subjects enrolled will be randomized (like flipping a coin) to the treatment group and half will be randomized to the control group. Both groups will receive the standard of care for pain management following total knee replacement surgery. Subjects in the treatment group will receive SPR's SPRINT Beta Peripheral Nerve Stimulation (PNS) System in addition to standard of care.

Eligibility

Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Scheduled to undergo a primary unilateral total knee replacement procedure Key

Exclusion criteria

* Body Mass Index \> 40 kg/m2 * Conditions that place the subject at increased risk of infection * History of valvular heart disease * Implanted electronic device * Bleeding disorder * Allergy to skin surface electrodes and/or medical-grade adhesive tapes * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
Average Knee Pain While WalkingPostoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported.
Number of Subjects That Experienced at Least One Study-Related Adverse Event30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study)At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here.

Secondary

MeasureTime frameDescription
Pain Right Now as Measured by the Brief Pain InventoryBaseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA)Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used.
Amount of Analgesic UsageVisits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA))Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis.
Number of Subjects That Experienced at Least One Opioid-Related Side EffectBaseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA))Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects.
Timed Up and Go (TUG) TestVisit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA)Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline.
Six Minute Walk Test (6MWT)Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA)The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline.
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA)The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point.
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA)The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from very much worse to very much improved as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered Meaningful Improvements; similarly, ratings of Much- or Very Much Worse are categorized as Meaningfully Worse. Ratings of Minimally Improved, No Change, or Minimally Worse are considered Minimal or No Change.
Pain Catastrophizing Scale (PCS)Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA)The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents not at all, and 4 represents all the time. The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects.
Average Knee Pain Over the Last 24 HoursPostoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.
Subject Satisfaction SurveyVisit 8 (4-weeks post-total knee arthroplasty (TKA))Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable.
Number of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA)Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point.
Subject's Use of Device (Compliance)Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA)The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint.
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)1-week post-Total Knee Arthroplasty (TKA)Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below.
Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)1-week post-Total Knee Arthroplasty (TKA)Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: During this hospital stay, did you need medicine for pain?
Inpatient Pain Management Experience Survey (Discharge Facility)1-week post-Total Knee Arthroplasty (TKA)Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below.
Inpatient Pain Management Experience Survey (Overall Rating of Hospital)1-week post-Total Knee Arthroplasty (TKA))Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents worst hospital possible and 10 represents best hospital possible. The median score for each group is reported.
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came firstParticipants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated.
Average Knee Pain at RestPostoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.

Countries

United States

Participant flow

Recruitment details

Recruitment began in July 2017 (with first subject enrollment in September 2017) and was concluded in February 2020. Subjects were screened from the available pool of candidates scheduled to undergo a primary unilateral total knee replacement procedure.

Pre-assignment details

After obtaining informed consent, subjects were evaluated for eligibility.

Participants by arm

ArmCount
Treatment Group
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
18
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
23
Total41

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
ConsentedScreen failure before enrollment400
ConsentedScreen failure before randomization200
ConsentedTKA cancelled after enrollment100
ConsentedWithdrawn from study1200
Study EnrollmentTKA cancelled after enrollment001
Study EnrollmentWithdrawn from study066

Baseline characteristics

CharacteristicTreatment GroupControl GroupTotal
Affected Leg
Left Leg
10 Participants7 Participants17 Participants
Affected Leg
Right Leg
8 Participants15 Participants23 Participants
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
9 Participants11 Participants20 Participants
Age, Categorical
Between 18 and 65 years
9 Participants11 Participants20 Participants
Age, Continuous65.0 years
STANDARD_DEVIATION 5.5
63.0 years
STANDARD_DEVIATION 10.3
63.9 years
STANDARD_DEVIATION 8.4
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants21 Participants39 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants1 Participants3 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
16 Participants21 Participants37 Participants
Reason for Total Knee Arthroplasty (TKA)
Degenerative Joint Disease
0 Participants1 Participants1 Participants
Reason for Total Knee Arthroplasty (TKA)
Osteoarthritis
16 Participants21 Participants37 Participants
Reason for Total Knee Arthroplasty (TKA)
Post-Traumatic Arthritis
2 Participants0 Participants2 Participants
Region of Enrollment
United States
18 participants23 participants41 participants
Sex: Female, Male
Female
12 Participants12 Participants24 Participants
Sex: Female, Male
Male
6 Participants10 Participants16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 180 / 23
other
Total, other adverse events
12 / 189 / 23
serious
Total, serious adverse events
2 / 183 / 23

Outcome results

Primary

Average Knee Pain While Walking

All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported.

Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)

Population: Per Protocol Set

ArmMeasureValue (MEAN)Dispersion
Treatment GroupAverage Knee Pain While Walking3.70 Scores on a scaleStandard Deviation 1.97
Control GroupAverage Knee Pain While Walking4.14 Scores on a scaleStandard Deviation 1.49
Primary

Number of Subjects That Experienced at Least One Study-Related Adverse Event

At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here.

Time frame: 30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study)

Population: All enrolled Treatment Group subjects

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Treatment GroupNumber of Subjects That Experienced at Least One Study-Related Adverse Event8 Participants
Secondary

Amount of Analgesic Usage

Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis.

Time frame: Visits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA))

Population: Per Protocol Set - Data were not available for one Control Group subject at Visits 6-8.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupAmount of Analgesic UsageVisit 5 (1-week Post-TKA)29.9 MME
Treatment GroupAmount of Analgesic UsageVisit 6 (2-weeks Post-TKA)21.4 MME
Treatment GroupAmount of Analgesic UsageVisit 7 (3-weeks Post-TKA)13.6 MME
Treatment GroupAmount of Analgesic UsageVisit 8 (4-weeks Post-TKA)11.4 MME
Treatment GroupAmount of Analgesic UsageAverage Across Visits 5-819.1 MME
Control GroupAmount of Analgesic UsageAverage Across Visits 5-816.8 MME
Control GroupAmount of Analgesic UsageVisit 8 (4-weeks Post-TKA)2.9 MME
Control GroupAmount of Analgesic UsageVisit 6 (2-weeks Post-TKA)22.5 MME
Control GroupAmount of Analgesic UsageVisit 5 (1-week Post-TKA)31.4 MME
Control GroupAmount of Analgesic UsageVisit 7 (3-weeks Post-TKA)17.1 MME
Secondary

Average Knee Pain at Rest

All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.

Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))

Population: Per Protocol Set

ArmMeasureValue (MEAN)Dispersion
Treatment GroupAverage Knee Pain at Rest2.86 score on a scaleStandard Deviation 1.23
Control GroupAverage Knee Pain at Rest3.48 score on a scaleStandard Deviation 1.33
Secondary

Average Knee Pain Over the Last 24 Hours

All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.

Time frame: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))

Population: Per Protocol Set

ArmMeasureValue (MEAN)Dispersion
Treatment GroupAverage Knee Pain Over the Last 24 Hours3.24 score on a scaleStandard Deviation 1.52
Control GroupAverage Knee Pain Over the Last 24 Hours4.32 score on a scaleStandard Deviation 1.34
Secondary

Inpatient Pain Management Experience Survey (Discharge Facility)

Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below.

Time frame: 1-week post-Total Knee Arthroplasty (TKA)

Population: Per Protocol Set - Data were not available for three Control Group subjects.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Treatment GroupInpatient Pain Management Experience Survey (Discharge Facility)Someone else's home0 Participants
Treatment GroupInpatient Pain Management Experience Survey (Discharge Facility)Another healthcare facility0 Participants
Treatment GroupInpatient Pain Management Experience Survey (Discharge Facility)Own home7 Participants
Control GroupInpatient Pain Management Experience Survey (Discharge Facility)Someone else's home1 Participants
Control GroupInpatient Pain Management Experience Survey (Discharge Facility)Another healthcare facility1 Participants
Control GroupInpatient Pain Management Experience Survey (Discharge Facility)Own home11 Participants
Secondary

Inpatient Pain Management Experience Survey (Overall Rating of Hospital)

Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents worst hospital possible and 10 represents best hospital possible. The median score for each group is reported.

Time frame: 1-week post-Total Knee Arthroplasty (TKA))

Population: Per Protocol Set - Data were not available for three Control Group subjects.

ArmMeasureValue (MEDIAN)
Treatment GroupInpatient Pain Management Experience Survey (Overall Rating of Hospital)10 score on a scale
Control GroupInpatient Pain Management Experience Survey (Overall Rating of Hospital)10 score on a scale
Secondary

Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)

Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below.

Time frame: 1-week post-Total Knee Arthroplasty (TKA)

Population: Per Protocol Set - Data were not available for three Control Group subjects.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Never0 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Sometimes1 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Usually3 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Always3 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Never0 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Sometimes0 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Usually1 Participants
Treatment GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Always6 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Always10 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Never0 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Never0 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Sometimes3 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Usually2 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Usually4 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During hospital stay, how often did hospital staff do everything they could to help with your pain?Sometimes1 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Management During Hospital Stay)During this hospital stay, how often was your pain well controlled?Always6 Participants
Secondary

Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)

Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: During this hospital stay, did you need medicine for pain?

Time frame: 1-week post-Total Knee Arthroplasty (TKA)

Population: Per Protocol - Data were not available for three Control Group subjects

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Treatment GroupInpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)6 Participants
Control GroupInpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)13 Participants
Secondary

Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty

Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point.

Time frame: Visit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA)

Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 6, two Visit 9, and three at Visit 10.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 5 (1-week Post-TKA)2 Count of visits
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 6 (2-weeks Post-TKA)3 Count of visits
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 7 (3-weeks Post-TKA)2 Count of visits
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 8 (4-weeks Post-TKA)2 Count of visits
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 9 (2-months Post-TKA)9 Count of visits
Treatment GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 10 (3-months Post-TKA)8 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 9 (2-months Post-TKA)5 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 5 (1-week Post-TKA)2 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 8 (4-weeks Post-TKA)2 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 6 (2-weeks Post-TKA)3 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 10 (3-months Post-TKA)6 Count of visits
Control GroupNumber of Physical Therapy Sessions Attended Following Total Knee ArthroplastyVisit 7 (3-weeks Post-TKA)3 Count of visits
Secondary

Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey

The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from very much worse to very much improved as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered Meaningful Improvements; similarly, ratings of Much- or Very Much Worse are categorized as Meaningfully Worse. Ratings of Minimally Improved, No Change, or Minimally Worse are considered Minimal or No Change.

Time frame: Visits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA)

Population: Per Protocol Set: Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: one at Visit 4, one at Visit 6, one at Visit 9, three at Visit 10, and two at Visit 11.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Minimal or No Change5 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Meaningfully Worse2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Meaningful Improvement1 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Minimal or No Change5 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Meaningful Improvement2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Minimal or No Change3 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Minimal or No Change3 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Meaningfully Worse2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Meaningful Improvement2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Minimal or No Change3 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Meaningfully Worse2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Minimal or No Change3 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Meaningfully Worse2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Minimal or No Change3 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Meaningful Improvement6 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Minimal or No Change1 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Meaningfully Worse0 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Meaningful Improvement6 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Meaningfully Worse1 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Meaningfully Worse2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Meaningful Improvement2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Meaningful Improvement2 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Meaningful Improvement4 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Meaningfully Worse0 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Minimal or No Change0 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Meaningfully Worse0 Participants
Treatment GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Meaningful Improvement0 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Minimal or No Change7 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Meaningful Improvement1 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Minimal or No Change14 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Meaningfully Worse0 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 3 (Day of TKA)Meaningfully Worse1 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Meaningful Improvement3 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Meaningful Improvement4 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Meaningful Improvement9 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Meaningfully Worse2 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Meaningfully Worse1 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Meaningful Improvement3 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Minimal or No Change4 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Minimal or No Change11 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Meaningful Improvement12 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Minimal or No Change11 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 10 (3-months Post-TKA)Meaningfully Worse0 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 6 (2-weeks Post-TKA)Meaningfully Worse1 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Meaningful Improvement6 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Meaningful Improvement3 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 4 (In-Hospital)Minimal or No Change9 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 7 (3-weeks Post-TKA)Minimal or No Change12 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Meaningfully Worse1 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Meaningfully Worse0 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 8 (4-weeks Post-TKA)Minimal or No Change9 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 5 (1-week Post-TKA)Meaningfully Worse2 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 9 (2-months Post-TKA)Meaningful Improvement8 Participants
Control GroupNumber of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) SurveyVisit 11 (12-months Post-TKA)Minimal or No Change2 Participants
Secondary

Number of Subjects That Experienced at Least One Opioid-Related Side Effect

Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects.

Time frame: Baseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA))

Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 6 and Visit 11.~Data were not available for the following Control Group subjects: one at Visits 5, 6, 7, and 9, and three at Visits 10 and 11.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 11 (12-months Post-TKA)0 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectBaseline0 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 4 (In-Hospital)3 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 5 (1-week Post-TKA)3 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 6 (2-weeks Post-TKA)3 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 7 (3-weeks Post-TKA)2 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 8 (4-weeks Post-TKA)1 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 10 (3-months Post-TKA)0 Participants
Treatment GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 9 (2-months Post-TKA)0 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 11 (12-months Post-TKA)0 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 7 (3-weeks Post-TKA)6 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectBaseline0 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 10 (3-months Post-TKA)0 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 4 (In-Hospital)7 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 8 (4-weeks Post-TKA)4 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 5 (1-week Post-TKA)9 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 9 (2-months Post-TKA)0 Participants
Control GroupNumber of Subjects That Experienced at Least One Opioid-Related Side EffectVisit 6 (2-weeks Post-TKA)8 Participants
Secondary

Pain Catastrophizing Scale (PCS)

The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents not at all, and 4 represents all the time. The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects.

Time frame: Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA)

Population: Per Protocol Set - Data were not available for three Control Group subjects at Visit 10.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupPain Catastrophizing Scale (PCS)Visit 1 (Baseline)7 score on a scale
Treatment GroupPain Catastrophizing Scale (PCS)Visit 8 (4-weeks Post-TKA)6 score on a scale
Treatment GroupPain Catastrophizing Scale (PCS)Visit 10 (3-months Post-TKA)1 score on a scale
Control GroupPain Catastrophizing Scale (PCS)Visit 1 (Baseline)7 score on a scale
Control GroupPain Catastrophizing Scale (PCS)Visit 10 (3-months Post-TKA)0 score on a scale
Control GroupPain Catastrophizing Scale (PCS)Visit 8 (4-weeks Post-TKA)4 score on a scale
Secondary

Pain Right Now as Measured by the Brief Pain Inventory

Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents No Pain and 10 represents Pain as bad as you can imagine. The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used.

Time frame: Baseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA)

Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 3 and for one Control Group subject at Visit 6.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupPain Right Now as Measured by the Brief Pain InventoryVisit 3 (Day of TKA)2.0 Scores on a scale
Treatment GroupPain Right Now as Measured by the Brief Pain InventoryVisit 6 (2-weeks Post-TKA)2.0 Scores on a scale
Treatment GroupPain Right Now as Measured by the Brief Pain InventoryVisit 4 (In-Hospital)2.0 Scores on a scale
Treatment GroupPain Right Now as Measured by the Brief Pain InventoryVisit 8 (4-weeks Post-TKA)1.0 Scores on a scale
Treatment GroupPain Right Now as Measured by the Brief Pain InventoryBaseline1.0 Scores on a scale
Control GroupPain Right Now as Measured by the Brief Pain InventoryVisit 8 (4-weeks Post-TKA)1.0 Scores on a scale
Control GroupPain Right Now as Measured by the Brief Pain InventoryBaseline3.0 Scores on a scale
Control GroupPain Right Now as Measured by the Brief Pain InventoryVisit 3 (Day of TKA)2.0 Scores on a scale
Control GroupPain Right Now as Measured by the Brief Pain InventoryVisit 4 (In-Hospital)3.5 Scores on a scale
Control GroupPain Right Now as Measured by the Brief Pain InventoryVisit 6 (2-weeks Post-TKA)3.0 Scores on a scale
Secondary

Six Minute Walk Test (6MWT)

The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline.

Time frame: Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA)

Population: Per Protocol Set - Data were not available for one Control Group subject at Visit 6.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupSix Minute Walk Test (6MWT)Visit 1 (Baseline)458.5 meters
Treatment GroupSix Minute Walk Test (6MWT)Visit 6 (2-weeks Post-TKA)280.0 meters
Treatment GroupSix Minute Walk Test (6MWT)Visit 8 (4-weeks Post-TKA)410.0 meters
Control GroupSix Minute Walk Test (6MWT)Visit 1 (Baseline)351.3 meters
Control GroupSix Minute Walk Test (6MWT)Visit 6 (2-weeks Post-TKA)281.0 meters
Control GroupSix Minute Walk Test (6MWT)Visit 8 (4-weeks Post-TKA)329.0 meters
Secondary

Subject Satisfaction Survey

Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable.

Time frame: Visit 8 (4-weeks post-total knee arthroplasty (TKA))

Population: Per Protocol Set

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Treatment GroupSubject Satisfaction SurveyTolerated Lead placement with some or no discomfort7 Participants
Treatment GroupSubject Satisfaction SurveyReported stimulation felt comfortable/soothing5 Participants
Treatment GroupSubject Satisfaction SurveyReported immediate pain relief (0-5 minutes)4 Participants
Treatment GroupSubject Satisfaction SurveyWould recommend therapy to a friend7 Participants
Treatment GroupSubject Satisfaction SurveyWould want to receive again if having another TKA7 Participants
Treatment GroupSubject Satisfaction SurveyPrefer stimulation therapy to pain medication use7 Participants
Treatment GroupSubject Satisfaction SurveyWanted stimulation for longer time period before TKA surgery1 Participants
Treatment GroupSubject Satisfaction SurveyWanted stimulation for longer time period after TKA surgery1 Participants
Secondary

Subject's Use of Device (Compliance)

The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint.

Time frame: Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA)

Population: Per Protocol Set - Treatment Group. Data were not available for the femoral or sciatic Leads for one subject at Visit 4 and two subjects at Visit 6. One subject at Visits 4, 6, 8 did not have a sciatic Lead in place.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupSubject's Use of Device (Compliance)Visit 4 (In-Hospital): Femoral Lead79 hours
Treatment GroupSubject's Use of Device (Compliance)Visit 4 (In-Hospital): Sciatic Lead73 hours
Treatment GroupSubject's Use of Device (Compliance)Visit 6 (2-weeks Post-TKA): Femoral Lead358 hours
Treatment GroupSubject's Use of Device (Compliance)Visit 6 (2-weeks Post-TKA): Sciatic Lead373.5 hours
Treatment GroupSubject's Use of Device (Compliance)Visit 8 (4-weeks Post-TKA): Femoral Lead646 hours
Treatment GroupSubject's Use of Device (Compliance)Visit 8 (4-weeks Post-TKA): Sciatic Lead633 hours
Secondary

Timed Up and Go (TUG) Test

Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline.

Time frame: Visit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA)

Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 1 (subject was unable to complete test), three at Visit 4 (two subjects were unable to complete test), and one at Visit 6.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupTimed Up and Go (TUG) TestTime at Visit 1 (Baseline)12.44 seconds
Treatment GroupTimed Up and Go (TUG) TestTime at Visit 4 (In-Hospital)41.80 seconds
Treatment GroupTimed Up and Go (TUG) TestTime at Visit 6 (2-weeks Post-TKA)14.28 seconds
Treatment GroupTimed Up and Go (TUG) TestTime at Visit 8 (4-weeks Post-TKA)10.68 seconds
Control GroupTimed Up and Go (TUG) TestTime at Visit 8 (4-weeks Post-TKA)10.38 seconds
Control GroupTimed Up and Go (TUG) TestTime at Visit 1 (Baseline)10.25 seconds
Control GroupTimed Up and Go (TUG) TestTime at Visit 6 (2-weeks Post-TKA)15.93 seconds
Control GroupTimed Up and Go (TUG) TestTime at Visit 4 (In-Hospital)42.22 seconds
Secondary

Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)

Participants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated.

Time frame: From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came first

Population: Per Protocol Set- Treatment Group: Data were not available for: 1 subject in walked without assistive device, 1 in cleared to drive. 1 subject did not cease opioids during the study. 5 subjects were retired and did not work.~Control Group: Data were not collected for: 3 in walked without assistive device, 2 in able to climb stairs, 1 in cleared to drive, 1 in opioid cessation (2 more did not cease opioids during the study). 9 subjects were retired and did not work.

ArmMeasureGroupValue (MEDIAN)
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Discharged from hospital1 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked without assistive device24 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked 30 meters1 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Able to climb flight of stairs1 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Cleared to drive21 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Returned to work9 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Cessation of all opioid medications37 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked with assistive device0 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Met hospital discharge criteria1 days
Treatment GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Pain controlled without nerve block3 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked with assistive device1 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Pain controlled without nerve block2 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Returned to work20 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked without assistive device16 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Able to climb flight of stairs13 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Walked 30 meters4 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Cessation of all opioid medications28 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Discharged from hospital1 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Met hospital discharge criteria1 days
Control GroupTime to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)Cleared to drive21 days
Secondary

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point.

Time frame: Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA)

Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: three at Visit 3, one at Visit 6, three at Visit 10, and two at Visit 11.

ArmMeasureGroupValue (MEAN)Dispersion
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 11 (12-months Post-TKA)4.83 score on a scaleStandard Deviation 4.36
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 3 (Day of TKA)68.71 score on a scaleStandard Deviation 47.87
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 6 (2-weeks Post-TKA)58.57 score on a scaleStandard Deviation 33.24
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 8 (4-weeks Post-TKA)40.29 score on a scaleStandard Deviation 26.56
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 10 (3-months Post-TKA)22.86 score on a scaleStandard Deviation 22.13
Treatment GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 1 (Baseline)87.00 score on a scaleStandard Deviation 30.34
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 10 (3-months Post-TKA)29.38 score on a scaleStandard Deviation 21.05
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 1 (Baseline)111.31 score on a scaleStandard Deviation 38.78
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 11 (12-months Post-TKA)12.79 score on a scaleStandard Deviation 20
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 3 (Day of TKA)99.23 score on a scaleStandard Deviation 51.25
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 8 (4-weeks Post-TKA)51.94 score on a scaleStandard Deviation 30.83
Control GroupWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Visit 6 (2-weeks Post-TKA)81.13 score on a scaleStandard Deviation 38.98

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026